Elyxium Wealth’s Novartis NVS Stock Holding History

Elyxium Wealth’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,820	Closed	-$278K	–	301
2026 Q1	$278K	Sell	1,820 -982	-35%	-$151K	0.09%	139
2025 Q4	$386K	Buy	2,802 +240	+9%	+$31.4K	0.11%	123
2025 Q3	$329K	Buy	+2,562	New	+$313K	0.11%	131

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Elyxium Wealth's NVS Position: Q2 2026 in Review

Elyxium Wealth sold out of Novartis (NVS) in Q2 2026, closing a stake of 1,820 shares — an estimated $278K sold.

Elyxium Wealth first reported a position in NVS in Q3 2025 and held it in 3 quarters. The position peaked at $386K in Q4 2025. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Elyxium Wealth reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
Elyxium Wealth sold 1,820 Novartis shares in Q2 2026, an estimated $278K.
Elyxium Wealth first reported a position in Novartis in Q3 2025 and held it in 3 quarters.
Elyxium Wealth's Novartis position peaked at $386K in Q4 2025.
1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Elyxium Wealth's 13F filing for Q2 2026, filed 3 Aug 2026.